We bring together drug screening assets to support efficiency of screening programs run by global Biopharma R&D. The screening assets of Sristi forms an innovative platform technology that offer target & lead intelligence, compound libraries and assayed primary human cells . The company follows a hybrid business model that integrates CRO & Captive research. Global Bio-Pharma SMEs & Bio-Screening research Products suppliers are our focus clients.